Previous close | 0.1200 |
Open | 0.1250 |
Bid | 0.1250 x N/A |
Ask | 0.1300 x N/A |
Day's range | 0.1200 - 0.1300 |
52-week range | 0.0420 - 0.1850 |
Volume | |
Avg. volume | 2,337,847 |
Market cap | 136.521M |
Beta (5Y monthly) | -0.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance with Arovella Therapeutics Ltd (ASX: ALA). This collaboration emphasizes the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-iNKT cell therapy.